MPN

Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs.

Patricia K. Koenig, patient advocate and 2016 MPN Hero, discusses living with polycythemia vera (PV).

The clinical hold on pacritinib was recently lifted by the US Food and Drug Administration (FDA).

Erin H. Blackwell, R.N., B.S.N., O.C.N., oncology nurse and 2016 MPN Hero, discusses what to discuss with newly diagnosed patients with MPNs to ensure the best possible care.

Bonnie Joyce Blankert, caregiver and 2016 MPN Hero, discusses the importance of remaining calm when caregiving for a loved one with MPN who recently had a stem cell transplant.

After being diagnosed with polycythemia vera, David Wallace, who publishes PV Reporter and MPN Cancer Connection, quickly learned that he must be his own advocate.

Ann Brazeau, founder and CEO of MPN Advocacy & Education International and a 2016 MPN Hero, discusses the importance and benefits of MPN support groups.

A recent study examined the symptoms and impairments for patients with MPNs.

Oncologist, researcher and Pulitzer Prize-winning author Siddhartha Mukherjee, M.D., Ph.D, talked with CURE on the future of treating MPNs.

For the first time in history, MPN guidelines have been set by the NCCN.

Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).

Ropeginterferon alfa-2b is noninferior to hydroxyurea (HU) when it comes to complete hematologic response to treat PV.

Recent studies found that for certain patients with CML, it is possible to safely reduce or stop TKI treatment.

Eight individuals were honored for their dedication to MPN at the 2016 MPN Heroes™ celebration.

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.

Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.

Srdan Verstovsek, M.D., Ph.D. talks to CURE about recent advances in treating MPNs.

A recent study showed that patients with MPNs treated with Jakafi off a clinical trial still benefited from the drug.

Pacritinib decreased spleen size, but did not improve total symptom scores in a group of patients with myelofibrosis.

The MPN Research Foundation wants to empower patients through initiatives such as their MPN patient registry.

Barbara Van Husen, president of the MPN Research Foundation, discusses how after the discovery of the JAK2 mutation in 2005, MPN research and treatment advances proliferated. Now, Van Husen says, it is one of the most active areas of hematological research

CURE recently interviewed Naveen Pemmaraju to discuss the unique aspects of the MPN community, the pitfalls of social media and the importance of patients and physicians interacting.

Jennifer Arnold, our MPN Heroes guest speaker, a physician and star of TLC’s reality TV show “The Little Couple,” discusses the importance of doctors and caregivers taking a moment to listen to patients and see how they are feeling.

Many patients with myeloproliferative neoplasms often are burdened with sexual dysfunction, a study says. However, the issue is not often discussed between patients and their doctors.

Susan Melvin Hill, patient advocate, tells her MPN story and discusses how she helps patients with myeloproliferative neoplasms (MPNs) in Idaho.

Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Imagine a beautiful expanse in the Southwest, a desert landscape stretching across sandswept miles until it reaches mountains that rise into the starry night sky.

The FDA has placed a full clinical hold on pacritinib following reports of patient deaths related to intracranial hemorrhage, cardiac failure and cardiac arrest in the phase 3 PERSIST-2 trial.

An essay honoring Emily A. Knight, RN, OCN [Mayo Clinic Cancer Center in Scottsdale, Arizona.

Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.